Stockwatch: Silence – Nobels and whistles
This article was originally published in Scrip
The 2011 Nobel Prize in Medicine was awarded on 3 October to Bruce Beutler and Jules Hoffmann for discoveries in innate immunity, and to Ralph Steinman for his discovery of the dendritic cell and its role in adaptive immunity. While the headline news is that Steinman's award will proceed even though he died (on 30 September) without knowing of the prize, the timing of the award can serve to remind those in the life sciences that good science – even Nobel-quality science – is not a surrogate for or predictor of subsequent commercial success.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.